Holen Sie sich die Stockscreener-App
150.65
1.31%
1.95
Handel nachbörslich:
151.88
1.23
+0.82%
Glaukos Corp Aktie (GKOS) Neueste Nachrichten
Glaukos Corp stock and its role in eye disease treatment - AD HOC NEWS
Form 144 GLAUKOS Corp For: 6 July By Investing.com - Investing.com South Africa
Glaukos (NYSE: GKOS) files Form 144 to sell 10,000 shares - Stock Titan
Glaukos stock rating reiterated at Outperform by William Blair - Investing.com
Glaukos Rises as Reimbursement Milestone and Recent Pipeline Updates Support Sentiment - Quiver Quantitative
Glaukos stock hits 52-week high at 148.12 USD - Investing.com
Form 144 GLAUKOS Corp For: 1 July - Investing.com UK
Form 144 GLAUKOS Corp For: 1 July By Investing.com - Investing.com Canada
GKOS (GKOS) insider sells 3,630 shares total across April and June 2026 - Stock Titan
GKOS Reiterated by Piper Sandler -- Price Target Maintained at $165 - GuruFocus
Piper Sandler reiterates Glaukos stock rating on iDose headwinds - Investing.com
Piper Sandler reiterates Glaukos stock rating on iDose headwinds By Investing.com - Investing.com India
Form 4 Glaukos Corp For: 29 June By Investing.com - Investing.com South Africa
Glaukos (NYSE: GKOS) CEO updates trust holdings, uses shares for tax withholding - Stock Titan
Form 4 Glaukos Corp For: 29 June - Investing.com UK
Glaukos (NYSE: GKOS) president has 1,056 shares withheld for taxes - Stock Titan
Glaukos (GKOS) CDO reports 483-share tax withholding, holds 88,350 shares - Stock Titan
Enterprise value to EBIT forward of Glaukos Corp – XETR:6GJ - TradingView
Price to book forward of Glaukos Corp – XETR:6GJ - TradingView
Enterprise value to EBITDA forward of Glaukos Corp – XETR:6GJ - TradingView
Goldman Sachs Small Cap Equity Insights Fund's Glaukos Corp(GKOS) Holding History - GuruFocus
Glaukos Corp Actuals & Estimates (NYSE:GKOS) - TradingView
Glaukos Moves Into Demodex Blepharitis Space - Orange County Business Journal
Midday Stock Roundup: Glaukos Rises 4% After Phase 2 Enrollment Completed - Orange County Business Journal
Glaukos completes enrollment in phase 2 blepharitis study - Investing.com
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis - BioSpace
Glaukos completes enrollment in phase 2 blepharitis study By Investing.com - Investing.com Australia
Glaukos (GKOS) Completes Patient Enrollment in GLK-321 Study - GuruFocus
Glaukos fills 275-patient trial of eyelid-disease drug candidate - Stock Titan
Glaukos Corp (GKOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 4 Glaukos Corp For: 23 June By Investing.com - Investing.com Nigeria
Form 4 Glaukos Corp For: 23 June - Investing.com UK
Glaukos (NYSE: GKOS) director updates stock option grant to $106.52 strike - Stock Titan
Glaukos (NYSE: GKOS) director Leana Wen awarded 2,987 stock options at $106.52 - Stock Titan
GLAUKOS (GKOS) director Stapley gets 2,987 options at corrected $106.52 strike - Stock Titan
Glaukos (NYSE: GKOS) amends Form 4, sets option strike at $106.52 - Stock Titan
Glaukos (GKOS) corrects director option price in amended Form 4 - Stock Titan
Glaukos (NYSE: GKOS) corrects strike on 2,987 director options - Stock Titan
Glaukos (NYSE: GKOS) director Denice Torres granted options and corrects exercise price - Stock Titan
Glaukos Corp (GKOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Glaukos Corp (GKOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Glaukos StockAnalyst coverage and long-term glaucoma focus - AD HOC NEWS
GKOS (Glaukos Corp) Shows Strong Trend Template Compliance and High Growth Momentum on ChartMill - ChartMill
Glaukos CDO Navratil sells $200,855 in company stock By Investing.com - Investing.com South Africa
Glaukos Corp (GKOS) Institutional Confidence - TradingKey
Glaukos Corp (GKOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Glaukos CDO Navratil sells $200,855 in company stock - Investing.com
Glaukos (GKOS) development chief sells 1,537 shares under 10b5-1 plan - Stock Titan
Glaukos Corp (GKOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Glaukos Corp (GKOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Glaukos Corp (GKOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
0.39%
0.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):